多层螺旋CT尿路造影对上尿路梗阻性疾病的诊断价值

目的 探讨多层螺旋CT尿路造影（MSCTU）在上尿路梗阻性疾病诊断中的价值。资料与方法 搜集经静脉肾盂造影（IVU）或其他影像学检查提示上尿路梗阻而原因不明的患者58例，均行MSCTU检查，在图像工作站对获得图像进行最大密度投影（MIP）、多平面重建（MPR）及容积再现（vRT）等三维后处理，获得泌尿系立体图像。结果 58例中上尿路结石20例，先天性畸形14例，输尿管癌11例，输尿管炎性狭窄3例，输尿管息肉2例，副肾血管压迫肾盂输尿管交接处2例，邻近器官疾病导致上尿路梗阻2例，以上病例均经手术或输尿管镜检查证实。另有4例无法确诊，诊断准确率为93．10％。结论 MSCTU通过MPR、MIP、VRT技术多角度观察能够更加清晰地显示出导致上尿路梗阻的病变及其形态，在上尿路梗阻病变诊断方面有独特的优势。     

Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo.

The objective of this study was to determine the effects of flavonoids on the in vitro monocarboxylate transporter 1 (MCT1)-mediated transport and in vivo disposition of the drug of abuse, gamma-hydroxybutyrate (GHB). The uptake of GHB in rat MCT1 gene-transfected MDA-MB231 cells was significantly decreased in the presence of the flavonoids apigenin, biochanin A, chrysin, diosemin, fisetin, genistein, hesperitin, kaempferol, luteolin, morin, narigenin, phloretin, and quercetin, but was not affected by the flavonoid glycosides phloridzin and rutin. The IC(50) values for luteolin, morin, and phloretin were 0.41 +/- 0.14, 6.41 +/- 2.01, and 2.57 +/- 0.48 microM, with the inhibition mechanism for luteolin being competitive. [(3)H]Kaempferol and [(3)H]biochanin A did not exhibit MCT1-mediated uptake, suggesting that these flavonoids are not substrates for MCT1. The combination of luteolin and phloretin inhibited the uptake of GHB in a synergistic manner; however, the combination of luteolin and morin was antagonistic. GHB 1000 mg/kg was administered to rats by i.v. bolus, with or without the concomitant administration of luteolin 10 mg/kg i.v. After luteolin treatment, the renal and total clearances of GHB were significantly increased, probably because of inhibition of the MCT1-mediated renal reabsorption of GHB, and the sleep time significantly decreased (121 +/- 5 min versus 165 +/- 10 min) compared with control rats. Overall, the results of this study indicate that flavonoids from food or herbal products may significantly alter the pharmacokinetics and pharmacodynamics of MCT substrates.     

结节性黄瘤病并发主动脉瓣狭窄1例

报告1例并发主动脉瓣狭窄的结节性黄瘤病，患独男，12岁。全身多发黄色结节12年，皮肤组织病理示真皮浅层大量泡沫细胞。心脏彩色多普勒超声诊断为主动脉瓣狭窄。     

先天性胃壁肌层缺损诊治体会

目的 探讨提高新生儿先天性胃壁肌层缺损治愈率的方法。方法 总结分析近年来收治的本症11例患儿(均经过病理检验证实)的临床及相关资料。结果 11例患儿中，8例存活，其中7例为近十年的病例。1例死亡，2例放弃治疗，均为十年以前的病例。在存活者中，经追踪观察及消化道造影检查，残胃有明显代偿性生长，患儿生长发育未受到明显的影响。结论 早期发现、及时手术、控制感染、术后营养、支持治疗，其预后良好。     

胃切除术后急性胆囊炎的微创治疗

目的：探讨胃切除后急性胆囊炎的微创治疗的方法和效果。方法：回顾性分析28例胃切除术后近期（<4周）并发急性胆囊炎患者的临床资料。全组均明确诊断后先行常规非手术治疗，经24h治疗后症状体征无缓解的病例加行B超引导下经皮经肝胆囊穿刺置管引流术(PTGD)。结果：5例经非手术治疗缓解;23例加行PTGH，穿刺置管成功率100%。置管抽吸胆汁后症状体征即明显减轻，3~7d后症状体征完全消失。结论：超声引导下经皮经肝胆囊穿刺置管引流术治疗胃切除术后近期并发急性胆囊炎效果确切，创伤小，患者恢复快，具有明显的优越性。     

超声引导下经皮经肝胆管穿刺置管引流在梗阻性黄疸病人中的应用

目的　评价超声引导下经皮经肝穿刺胆管置管引流 (UPTBD)对梗阻性黄疸病人的治疗价值。方法　对 1995年 1月至 2 0 0 2年 7月期间的 4 17例梗阻性黄疸病人进行 4 97次UPTBD治疗 ,并回顾总结他们的临床资料。结果　接受PTBD治疗共有 4 17例 (5 1例病人进行了两个胆管枝的PTBD) ,穿刺成功率达 93.2 % (4 36 / 4 6 8) ,32例首次穿刺失败的病人有 2 9例进行了第二次穿刺置管 ,全部成功。发生胆汁漏 /胆汁性腹膜炎 9例 ,胆道出血 8例 ,感染性休克 1例 ,无腹腔出血、后腹膜血肿、气胸等其他并发症。对 6 4例置管引流患者进行肝功能检测 ,与穿刺前相比 ,引流后 1周和 3周检测病人血清胆红素、转氨酶均显著下降。结论　UPTBD是一项姑息性治疗梗阻性黄疸的快捷、安全、有效的方法     

1株诱变枯草杆菌溶栓酶性质研究的初探

目的 对从1株诱变的枯草杆菌的发酵液中，通过分离纯化得到的一种活性较高的纤溶酶进行性质研究。方法 按胰酶活性测定法测其水解酪蛋白活性，用SDS-PAGE测定分子量，等电聚焦测定其等电点。采用硫酸酚法测定糖含量，并对其药理性质进行研究。结果 其水解酪蛋白活性为2.1U/mg，分子量为62kDa。等电点为8.5。含糖量为32%，并且发现该酶具有直接降解纤维蛋白的活性。结论 此纤溶酶具有较高的活性及药理价值。     

微创经皮肾镜取石术治疗上尿路结石

目的 探讨微创经皮肾镜取石术治疗上尿路结石的有效性和安全性.方法上尿路结石患者368例,平均年龄57岁.其中输尿管上段结石116例,结石大小(2.1±0.8)cm;肾结石252例,结石大小(4.6±1.4)cm,其中非鹿角形结石190例,结石大小(3.2±1.1)cm,鹿角形结石62例,结石大小(7.6±1.6)cm.均采用微创经皮肾穿刺,输尿管镜下气压弹道或联合钬激光碎石治疗,对结石清除率和并发症等进行统计分析.结果 368例患者中单通道取石356例(96.7%),双通道12例(3.3%).一期取石344例(93.5%),二期取石24例(6.5%).总结石取净率为88.6%(326/368).平均手术时间73 min.一期取净结石者住院时间4～8 d,平均6 d.术后发热14例(3.8%);输血5例(1.4%);2例肾结石术后出血严重者经输血及超选择性肾动脉栓塞后治愈.结论 微创经皮肾镜取石术损伤小、住院时间短、术中出血及并发症少、结石清除率高、可重复取石,是治疗上尿路结石有效的微创手段.     

首例中国可视化人体心脏三维重建及临床意义

目的 对首例中国数字化可视人体的心脏进行三维重建，为心脏疾病的影像学诊断和外科手术提供三维解剖学依据。方法 将首例中国数字化可视人体心脏部分的薄层断面(层厚1．0mm)输入SGI工作站，经数据分割、对位重建、平滑处理和三维显示等步骤，完成对心脏结构的三维重建。结果 本研究完整地重建出了心脏结构，重建的结构能够以多结构、多彩色实体模型方式显示，可显示心脏内部各结构的空间位置和毗邻关系，可在三维空间伴置上绕任意轴旋转任意角度。结论 重建出的三维图像清晰地显示了心脏内部和整体的结构，实现了心脏的二维可视化。     

Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke.

Bone marrow stromal cells (MSCs) increase vascular endothelial growth factor (VEGF) expression and promote angiogenesis after stroke. Angiopoietin-1 (Ang1) and its receptor Tie2 mediate vascular integrity and angiogenesis as does VEGF and its receptors. In this study, we tested whether MSC treatment of stroke increases Ang1/Tie2 expression, and whether Ang1/Tie2 with VEGF/ vascular endothelial growth factor receptor 2 (VEGFR2) (Flk1), in combination, induced by MSCs enhances angiogenesis and vascular integrity. Male Wistar rats were subjected to middle cerebral artery occlusion (MCAo) and treated with or without MSCs. Marrow stromal cell treatment significantly decreased blood-brain barrier (BBB) leakage and increased Ang1, Tie2, and occludin (a tight junction protein) expression in the ischemic border compared with MCAo control. To further test the mechanisms of MSC-induced angiogenesis and vascular stabilization, cocultures of MSCs with mouse brain endothelial cells (MBECs) or astrocytes were performed. Supernatant derived from MSCs cocultured with MBECs significantly increased MBEC expression of Ang1/Tie2 and Flk1 compared with MBEC alone. Marrow stromal cells cocultured with astrocytes also significantly increased astrocyte VEGF and Ang1/Tie2 expression compared with astrocyte culture alone. Conditioned media from MSCs alone, and media from cocultures of MSCs with astrocytes or MBECs, all significantly increased capillary tube-like formation of MBEC compared with control Dulbecco's modified Eagle's medium media. Inhibition of Flk1 and/or Ang1 significantly decreased MSC-induced MBEC tube formation. Knockdown of Tie2 expression in MBECs significantly inhibited MSC-induced tube formation. Our data indicate MSC treatment of stroke promotes angiogenesis and vascular stabilization, which is at least partially mediated by VEGF/Flk1 and Ang1/Tie2.